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Accepted 9 April 2010Placental site trophoblastic tumors (PSTTs) are an extremely
rare form of gestational trophoblastic disease (GTD). Marchand
and Ewing made the first observations in 1895 and 1910,
respectively, and Kurman and Scully described the clinical and
pathological characteristics of PSTTs in 1976, when the term
trophoblastic pseudotumor was adopted to characterize the
apparently benign nature of the disease [1,2]. Subsequent case
reports have presented evidence of a sometimes aggressive,
malignant, and fatal course of the disease, and the name was
changed to PSTT in 1981 [3]. Histopathologically, PSTTs are
characterized by a neoplastic monomorphic population of
implantation-like intermediate trophoblastic cells, often as
sheets of polyhedral, rounded, or occasionally spindle-shaped
cells that infiltrate the myometrium extensively. Because of
the rarity of this type of tumor, there is little information about
its epidemiology and etiology, and few large series on diagnosis
and treatment have been published [4]. PSTTs are most often
seen in patients of reproductive age and can follow a normal
pregnancy, miscarriage, or GTD. Irregular vaginal bleeding is
the most common presenting feature, although a wide range of
other symptoms has also been reported, including galactorrhea,
virilization, nephrotic syndrome, and polycythemia [5]. We
report two cases of PSTT treated successfully in our clinic.
A 38-year-old woman had not menstruated for 12 months
after a term vaginal delivery during lactation and consulted
a gynecologist. Because of suspicious uterine signs and persis-
tent high beta-human chorionic gonadotropin (b-hCG) levels,
she was referred to our medical center. On ultrasound exami-
nation, we detected a 100 mm 90 mm 75 mm pelvic mass
in the uterine wall. Color Doppler ultrasound suggested a tumor
(Fig. 1). The b-hCG level measured previously and in our clinic
was persistently high. After curettage, the sample was revealed* Conflict of interest: The authors declare no conflict of interest.
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surgery, the uterus was large, soft, and extremely vascular, and
the tumor involved both ovaries (Fig. 2). The uterus was ligated
at the isthmus using a Foley catheter to limit bleeding. After
sampling the pelvic fluid, we performed a radical total abdom-
inal hysterectomy, bilateral salpingo-oophorectomy, pelvic
lymph node sampling, and omental sampling for staging, and
both hypogastric arteries were ligated for hemostasis. The
histopathology showed PSTT (Fig. 3). The tumor had invaded
the serosal surface. No metastasis was seen on cranial, chest,
or abdominal computed tomography. Combined chemotherapy
[etoposide, methotrexate, actinomycin D alternating with
cyclophosphamide and vincristine/oncovine (EMA/CO)] was
initiated postoperatively and followed with a weekly b-hCG.
The patient received six courses of EMA/CO.
A 34-year-old woman had a spontaneous abortion in the 2nd
month of pregnancy. She complained of vaginal bleeding for 2
months afterward. She visited another health care center, where
she was examined and diagnosed with a uterine leiomyoma,
and a laparotomy was performed. At surgery, the surgeons
suspected that the tumor was a degenerative leiomyoma and
partially removed it. Histopathological examination revealed
that it was a PSTT, and she was referred to our clinic. Her
physical examination was normal. On ultrasound examination,
the uterus measured 86 mm 50 mm and an 18 mm 16 mm
hyperechogenic area was seen on the posterior uterine wall.
The left ovary was normal and there was a simple 60 mm
50 mm cyst in the right ovary. The first b-hCG level was
763 mIU/mL and the other tumor markers were normal. The
histopathology is shown in Fig. 4. Immunohistochemical and
morphologic features of the cells correspond to those of inter-
mediate trophoblast. Immunohistochemically, the tumor cells
were positive for epithelial membrane antigen, hCG, and
placental alkaline phosphatase. After informing the patient,
a laparotomy and a total abdominal hysterectomy and right
ovarian cystectomy were performed. The postoperative speci-
mens were confirmed as PSTT. Postoperatively, the patientcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. A 100 mm 90 mm 75 mm size pelvic mass was not distinguished from uterine wall. Doppler velocimetry of the mass showed increased blood flow,
which was considered to be malign.
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CO and was followed with a weekly b-hCG.
Neither patient has had a recurrence in the 6e8 months
since surgery. Both patients are followed up regularly with
laboratory tests and radiological imaging.
PSTTs are extremely rare in GTD and have an unpredict-
able malignant potential and highly variable clinical course.
They can present as fulminant metastatic disease, resistant to
conventional treating modalities. PSTTs account for 0.31e2%
of all trophoblastic disease. The reported rate of PSTT to
choriocarcinoma is 1 of 138. The disease is usually seen in
young women, although cases have been reported in post-
menopausal women. The mean age at diagnosis is 31e33
years, and it can appear following any type of pregnancy [6].
The adverse factors affecting survival in PSTT were reported
as age above 35 years, interval since the last pregnancy of
more than 2 years, Stage III or IV deep myometrial invasion,Fig. 2. . The postoperative photograph of the case. Uterus was large, soft, and
included extremely vascular; in addition, the tumor penetrated both the
ovaries.maximum hCG level higher than 1000 mIU/mL, extensive
coagulative necrosis, high mitotic rate, and the presence of
cells with clear cytoplasm [7]. Our patients were 34 and 38
years old, and the tumor occurred after a term pregnancy in the
first patient and a spontaneous abortion in the second.
This tumor produces human placental lactogen (hPL) and
lower hCG levels than those seen in choriocarcinoma. Unlike
choriocarcinoma, the serum b-hCG level in PSTT is not
correlated with tumor burden or malignant behavior. Therefore,
b-hCG appears to have no predictive value and the disease may
still progress even if b-hCG levels are not elevated. The range
of serum b-hCG concentrations at diagnosis is lower than
1000 mIU/mL in 79% of the patients and lower than 500 mIU/
mL in 58% of the patients. We cannot measure hPL in our
laboratory. The b-hCG level was 337 mIU/mL in the first
patient and 763 mIU/mL in the second; these levels are lower
than those seen in choriocarcinoma. The most frequent pre-
senting symptom is vaginal bleeding (79%). In the FeltmateFig. 3. The tumor cells showing medium-sized intermediate trophoblastic cells
(hematoxylin-eosin stain, 100).
Fig. 4. Medium sized intermediate trophoblastic cells infiltrating the myo-
metrium (hematoxylin-eosin stain, 200).
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[8]. One of our patients had amenorrhea and the other had
vaginal bleeding.
The reported outcome of PSTT is highly variable. All cases
of metastasis to vital organs, such as the brain, result in
mortality despite all forms of treatment. In our first case, the
tumor extended to the parametrium, whereas the second was
limited to the uterine wall. Unlike choriocarcinoma, PSTT is
relatively resistant to chemotherapy. Consequently, surgery is
the mainstay of treatment. The most recent data from different
centers suggest that EMA alternating with etoposide and
cisplatin is the most effective treatment for metastatic or
recurrent PSTTs [7]. Schmid et al [9] reported that the prob-
ability of overall survival for PSTT cases was 70% and
recurrence-free survival was 73% and they also told that
surgery is the sufficient therapy for Stage I cases, whereas
combined surgery and chemotherapy is needed for Stage II,
III, and IV. We treated both cases with combined EMA/CO
chemotherapy; b-hCG levels subsequently decreased to thenormal range and have remained normal. There has been no
recurrence during the follow-up period.
In conclusion, PSTTs are extremely rare worldwide. This
type of tumor may be seen after term pregnancy or spontaneous
abortion and produces hPL and lower b-hCG levels than those
seen in choriocarcinoma. We suggest that gynecologists should
consider this tumor during the postpartum and postabortion
periods. With surgery and subsequent combined chemotherapy,
PSTT is curable.
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